Dr. Arturo Urrios

Principal

  • PhD in synthetic biology and microfluidics with distinction
  • MSc in biomedical research and MBA
  • Joined Wellington in 2019
  • Investment Analyst at M Ventures

EMAILCONTACTLINKEDIN

Things are only impossible until they are not.

— Jean-Luc Picard

Biography

Arturo joined Wellington Partners as an Associate in 2019 and was promoted to Senior Associate in 2020 and Principal in 2022.

Prior to joining Wellington Partners, Arturo worked as an Investment Analyst in the life science team of M Ventures in the Netherlands, where he helped to define business strategies for potential spin-offs and was involved in several investment processes, including Riffyn, Plexium, Pantheon Biosciences, and DNA Script. Prior to joining M Ventures, Arturo completed his post-doctoral studies, developing synthetic biology approaches for type 1 diabetes treatments and bioindustrial applications while freelancing in different start-ups supporting them with strategy and business development.

 

Arturo holds an MSc in biomedical research and a Ph.D. in biomedicine from Pompeu Fabra University in Barcelona, Spain, in the fields of cell signaling, synthetic biology, and biological computation, as well as an MBA from UPF Barcelona School of Management. He performed additional research in the Folch Lab at the University of Washington, Seattle, in the fields of 3D printing and microfluidics, resulting in several publications in prestigious journals.

During his academic trajectory, he received multiple distinctions such as a national graduation award (ranked 1st in Biomedical Sciences in Spain), La Caixa PhD fellowship, EMBO short-term fellowship, and an extraordinary PhD award.

Besides his activities at Wellington Partners, Arturo is actively involved in the European life science start-up ecosystem, mentoring within different programs, including the BII Advisory Group.